{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:40:47Z","timestamp":1792006847633,"version":"4.4.0"},"reference-count":40,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2016]]},"DOI":"10.5582\/irdr.2016.01023","type":"journal-article","created":{"date-parts":[[2016,4,24]],"date-time":"2016-04-24T18:07:56Z","timestamp":1461521276000},"page":"70-75","source":"Crossref","is-referenced-by-count":42,"title":["Cardiac manifestations of idiopathic pulmonary fibrosis"],"prefix":"10.5582","volume":"5","author":[{"given":"Abhinav","family":"Agrawal","sequence":"first","affiliation":[{"name":"Department of Medicine, Monmouth Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Medicine, Monmouth Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Miami\/JFK Medical Center Palm Beach Regional GME Consortium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cooper University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutuja R","family":"Sikachi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Lilavati Hospital & Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: Scoring system and survival model. Am J Respir Crit Care Med. 2001; 164:1171-1181.","DOI":"10.1164\/ajrccm.164.7.2003140"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174:810-816.","DOI":"10.1164\/rccm.200602-163OC"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, Collard HR. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014; 2:566-572.","DOI":"10.1016\/S2213-2600(14)70101-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015; 192:e3-19.","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: Connecting the dots. Am J Respir Crit Care Med. 2007; 175:875-880.","DOI":"10.1164\/rccm.200608-1153CC"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62:D42-50.","DOI":"10.1016\/j.jacc.2013.10.032"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62:D34-41.","DOI":"10.1016\/j.jacc.2013.10.029"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, Pochettino A, Kotloff RM. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003; 167:735-740.","DOI":"10.1164\/rccm.200210-1130OC"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006; 129:746-752.","DOI":"10.1378\/chest.129.3.746"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007; 132:998-1006.","DOI":"10.1378\/chest.06-3087"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: A parallel, randomized trial. Ann Intern Med. 2013; 158:641-649.","DOI":"10.7326\/0003-4819-158-9-201305070-00003"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Agostini C, Gurrieri C. Chemokine\/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc. 2006; 3:357-363.","DOI":"10.1513\/pats.200601-010TK"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ng CS, Wells AU, Padley SP. A CT sign of chronic pulmonary arterial hypertension: The ratio of main pulmonary artery to aortic diameter. J Thorac Imaging. 1999; 14:270-278.","DOI":"10.1097\/00005382-199910000-00007"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): Endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Heart J. 2016; 37:67-119.","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Zisman DA, Karlamangla AS, Ross DJ, Keane MP, Belperio JA, Saggar R, Lynch JP, 3rd, Ardehali A, Goldin J. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2007; 132:773-779.","DOI":"10.1378\/chest.07-0116"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Leuchte HH, Baumgartner RA, Nounou ME, Vogeser M, Neurohr C, Trautnitz M, Behr J. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med. 2006; 173:744-750.","DOI":"10.1164\/rccm.200510-1545OC"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nielsen TD, Bahnson T, Davis RD, Palmer SM. Atrial fibrillation after pulmonary transplant. Chest. 2004; 126:496-500.","DOI":"10.1378\/chest.126.2.496"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Azadani PN, Kumar UN, Yang Y, Scheinman MM, Hoopes CW, Marcus GM, Rifkin C, Olgin JE, Lee BK. Frequency of atrial flutter after adult lung transplantation. Am J Cardiol. 2011; 107:922-926.","DOI":"10.1016\/j.amjcard.2010.10.076"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shibata Y, Watanabe T, Osaka D, et al. Impairment of pulmonary function is an independent risk factor for atrial fibrillation: The Takahata study. Int J Med Sci. 2011; 8:514-522.","DOI":"10.7150\/ijms.8.514"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Orrego CM, Cordero-Reyes AM, Estep JD, Seethamraju H, Scheinin S, Loebe M, Torre-Amione G. Atrial arrhythmias after lung transplant: Underlying mechanisms, risk factors, and prognosis. J Heart Lung Transplant. 2014; 33:734-740.","DOI":"10.1016\/j.healun.2014.02.032"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Patane S, Marte F, Sturiale M, Dattilo G, Luzza F. Atrial flutter, ventricular tachycardia and changing axis deviation associated with scleroderma. Int J Cardiol. 2011; 153:e25-28.","DOI":"10.1016\/j.ijcard.2009.03.080"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kizer JR, Zisman DA, Blumenthal NP, Kotloff RM, Kimmel SE, Strieter RM, Arcasoy SM, Ferrari VA, Hansen-Flaschen J. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med. 2004; 164:551-556.","DOI":"10.1001\/archinte.164.5.551"},{"key":"23","unstructured":"23. Kowalewski M, Urban M, Mroczko B, Szmitkowski M. Proinflammatory cytokines (IL-6, TNF-alpha) and cardiac troponin I (cTnI) in serum of young people with ventricular arrhythmias. Pol Arch Med Wewn. 2002; 108:647-651. (in Polish)"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fibrosis and vascular disease: A population-based study. Am J Respir Crit Care Med. 2008; 178:1257-1261.","DOI":"10.1164\/rccm.200805-725OC"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Izbicki G, Ben-Dor I, Shitrit D, Bendayan D, Aldrich TK, Kornowski R, Kramer MR. The prevalence of coronary artery disease in end-stage pulmonary disease: Is pulmonary fibrosis a risk factor? Respir Med. 2009; 103:1346-1349.","DOI":"10.1016\/j.rmed.2009.03.012"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Nathan SD, Basavaraj A, Reichner C, Shlobin OA, Ahmad S, Kiernan J, Burton N, Barnett SD. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med. 2010; 104:1035-1041.","DOI":"10.1016\/j.rmed.2010.02.008"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Cicchitto G, Musella V, Acitorio M, Capuano N, Fiorenzano G, Owen CA, Polverino M, Polverino F. Idiopathic pulmonary fibrosis and coronary artery disease. Multidiscip Respir Med. 2014; 9:31.","DOI":"10.1186\/2049-6958-9-31"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Nathan SD, Weir N, Shlobin OA, Urban BA, Curry CA, Basavaraj A, Ahmad S, Kiernan J, Sheridan MJ, Earls JP. The value of computed tomography scanning for the detection of coronary artery disease in patients with idiopathic pulmonary fibrosis. Respirology. 2011; 16:481-486.","DOI":"10.1111\/j.1440-1843.2010.01919.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Raghu G, Collard HR, Egan JJ, et al. An official ATS\/ERS\/JRS\/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183:788-824.","DOI":"10.1164\/rccm.2009-040GL"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2083-2092.","DOI":"10.1056\/NEJMoa1402582"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM, Group CS. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet. 2011; 377:1760-1769.","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"32","unstructured":"32. Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, du Bois RM. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31:198-205."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Lancaster L, Albera C, Bradford WZ, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: Integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res. 2016; 3:e000105.","DOI":"10.1136\/bmjresp-2015-000105"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Avila G, Osornio-Garduno DS, Rios-Perez EB, Ramos-Mondragon R. Functional and structural impact of pirfenidone on the alterations of cardiac disease and diabetes mellitus. Cell Calcium. 2014; 56:428-435.","DOI":"10.1016\/j.ceca.2014.07.008"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Kluglich M, du Bois RM. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365:1079-1087.","DOI":"10.1056\/NEJMoa1103690"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2071-2082.","DOI":"10.1056\/NEJMoa1402584"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Idiopathic Pulmonary Fibrosis Clinical Research N, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012; 366:1968-1977.","DOI":"10.1056\/NEJMoa1113354"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 183:431-440.","DOI":"10.1164\/rccm.201006-0894CI"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005; 128:2393-2399.","DOI":"10.1378\/chest.128.4.2393"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Whelan TP, Dunitz JM, Kelly RF, Edwards LB, Herrington CS, Hertz MI, Dahlberg PS. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant. 2005; 24:1269-1274.","DOI":"10.1016\/j.healun.2004.10.014"}],"container-title":["Intractable & Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/5\/2\/5_2016.01023\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T07:40:36Z","timestamp":1498290036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/5\/2\/5_2016.01023\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2016.01023","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}